A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors

[1]  Amy P Abernethy,et al.  Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). , 2014, Journal of the National Cancer Institute.

[2]  Joon-Oh Park,et al.  A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. , 2014, European journal of cancer.

[3]  P. Ott,et al.  New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy , 2014, Drug, healthcare and patient safety.

[4]  Suzanne F. Jones,et al.  A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. , 2013, European journal of cancer.

[5]  H. Ueno,et al.  Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Delong Liu,et al.  MEK and the inhibitors: from bench to bedside , 2013, Journal of Hematology & Oncology.

[7]  K. Flaherty,et al.  Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.

[8]  K. Flaherty,et al.  Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.

[9]  Takayuki Yamaguchi,et al.  Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. , 2011, International journal of oncology.

[10]  J. Kissil,et al.  Notch1 functions as a tumor suppressor in a model of K-ras-induced pancreatic ductal adenocarcinoma. , 2010, Cancer research.

[11]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[12]  C. Der,et al.  Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer , 2007, Oncogene.

[13]  A. Azuma.  High prevalence of drug-induced pneumonia in Japan , 2007 .

[14]  高橋 聡,et al.  Common Terminology Criteria for Adverse Events (CTCAE) v3.0による胃癌術後合併症の解析 , 2006 .

[15]  J. Warmus,et al.  Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition , 2004, Nature Structural &Molecular Biology.

[16]  Richard Marais,et al.  The RAF proteins take centre stage , 2004, Nature Reviews Molecular Cell Biology.

[17]  J. Sebolt-Leopold,et al.  CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). , 2003, Seminars in oncology.

[18]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[19]  P. Shapiro.  Ras-MAP Kinase Signaling Pathways and Control of Cell Proliferation: Relevance to Cancer Therapy , 2002, Critical reviews in clinical laboratory sciences.

[20]  T. Jacks,et al.  Somatic activation of the K-ras oncogene causes early onset lung cancer in mice , 2001, Nature.